Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livmoniplimab +/- Budigalimab in Solid Tumors
NCT03821935Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2019
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 1, randomised, open-label trial of livmoniplimab in solid tumor, pancreatic adenocarcinoma (PDAC), urothelial carcinoma (UC) and 5 more (15 arms), sponsored by AbbVie Inc. Primary endpoints: Recommended Phase 2 Dose of Livmoniplimab Monotherapy, Recommended Phase 2 Dose of Livmoniplimab + Budigalimab and 1 more. Started Feb 2019; status: active, not recruiting.
02
Drugs
livmoniplimab
03
Conditions
solid tumorpancreatic adenocarcinoma (PDAC)urothelial carcinoma (UC)hepatocellular carcinoma (HCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03821935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821935.